Background: Little is known in human immunodeficiency virus (HIV)–positive women about how the combination of plasma HIV RNA level and CD4 ⁺ T-cell count is associated with the natural history of human papillomavirus (HPV) infection or about HPV reactivation—whether it occurs and with what frequency in HIV-positive women. Methods: HIV-positive (n = 1848) and -negative (n = 514) women were assessed at semiannual visits (total person-years = 5661) for cervicovaginal HPV with polymerase chain reaction assays and for squamous intraepithelial lesions (SILs) by Pap smear. We studied the prevalent detection of HPV and SILs with generalized estimating equations and the incident detection and persistence of HPV and SILs with multivariable Cox models. All statistical tests were two-sided. Results: We observed a strong interaction between the associations of CD4 ⁺ and plasma HIV RNA strata with both prevalent ( P_interaction = .002) and incident ( P_interaction = .001) detection of HPV. Indeed, the hazard ratio for incident HPV detection peaked between 4.0 and 5.0, with either a CD4 ⁺ count of less than 200 cells per mm ³ or an HIV RNA level of more than 100 000 copies per mL. Although incident HPV detection in all women was associated with the number of recent sex partners ( P_trend <.001), 22% of sexually inactive HIV-positive women with a CD4 ⁺ count of less than 200 cells/mm ³ also had at least one incidently detected HPV type. The association between CD4 ⁺ /HIV RNA strata and HPV persistence was statistically significantly smaller ( P <.001) than for incident HPV detection. SIL prevalence, incident detection, and persistence had similar associations with CD4 ⁺ /HIV RNA strata as HPV (above). Conclusion: In HIV-positive women, plasma HIV RNA level and CD4 ⁺ count in combination appear to have a strong and statistically interactive association with incident detection of HPV, some of which may reflect HPV reactivation (e.g., in sexually inactive women). The more moderate association between HIV coinfection and HPV persistence could partly explain why cervical cancer rates have not reached more epidemic proportions in HIV-positive women.